With regard to the first-line PROFILE 1014 (2) and second-line PROFILE 1007 (32) phase 3 trials for ALK(+) NSCLC, the median crizotinib PFS in the first-line trial seemed to be better (10.9 vs. 7.0 months). This evidence concerns the gene ALK and non-small cell lung carcinoma.